→ Slide right to see all seven columns / net-new sources. Columns never stack — scroll horizontally.
Anthropic launches Claude Science — aimed at researchers and pharma
Eric Kauderer-Abrams, Anthropic’s head of life sciences, told STAT this is “the single most important thing” at Anthropic. Claude Science is the life-sciences counterpart to Claude Code — built for drug discovery and laboratory research. Dario Amodei will also try Anthropic’s hand at developing drugs directly.
Did the FDA really clear an LLM? UpDoc claims first clearance for patient-facing AI
Startup UpDoc claims its diabetes app received the first FDA clearance for a “patient-facing large language model.” Public documents and independent experts suggest a tamer interpretation — but UpDoc CEO Sharif Vakili maintains the system is “way more complex” than regulators’ standard characterization.
Elevance sues government over $115M tied to Medicare Advantage star ratings
Elevance Health alleges that CMS’s recalculation of its MA quality ratings did not align with a recent court ruling, costing the insurer $115 million. Elevance joins SCAN in an expanding wave of MA Stars litigation against the federal government.
Epic heir-apparent Sumit Rana departs after 28 years
Sumit Rana — widely seen as successor to 82-year-old co-founder/CEO Judy Faulkner — is leaving Epic after writing the first version of MyChart. His departure leaves a significant succession question at the dominant EHR company with no named replacement.
Secret-shopper study: GLP-1 telehealth sites prescribe with minimal clinical oversight
A study probing 49 GLP-1 telehealth websites confirmed expert concerns: platforms dispense Wegovy, Ozempic, and compounded semaglutide with limited health-history review, no lab work, and no ongoing monitoring. The absence of rigorous prescribing standards creates downstream quality gaps that a high-performing primary care network is designed to close.
America’s employer health insurance is decaying — Bob Herman
After seven months of reporting, Bob Herman’s “out of pocket, out of reach” thesis: the employer-based system covering 150 million Americans is crumbling. Workers and businesses are getting soaked, costs are rising, and complexity is pushing employers to the breaking point. “I’m done. I just want to make hamburgers.”
Whistleblower taking on employer health benefits industry
Chris Deacon, who oversaw health benefits for New Jersey’s state workers, has become a whistleblower on how health care companies systematically extract margin from employers. Her front-row view documents the structural dynamics that allow insurers and PBMs to take advantage while employers and employees hold the bill.
ACO REACH PY2024: $2.5B gross savings, 24% YoY growth — model sunsets 2026
CMS released PY2024 REACH results: $2.5B gross savings ($88.04 PBPM), up 24% YoY. 2021-vintage ACOs drove the result: $758M net savings, 6.5% net savings rate. Participants hitting stride just as the model sunsets end-of-2026. Leaders: Oak Street, Iora, agilon, CenterWell, VillageMD. Notable losses: CVS and Vytalize combined ~$170M.
GOP blocks effort to end Medicare AI prior-authorization pilot
The Medicare pilot uses AI to approve or deny care in original Medicare — where prior authorization is rarely used. A congressional move to block the pilot failed along party lines, keeping CMS’s AI-automated prior-auth experiment live.
Novo Nordisk sues Eli Lilly over GLP-1 drug ads it calls deceptive
Novo filed a federal lawsuit arguing Lilly’s ads compare the highest doses of Zepbound and Mounjaro against lower doses of Wegovy and Ozempic — an apples-to-oranges comparison Novo calls deceptive. The GLP-1 market-share war escalates from competing commercials to federal court.
FDA questions efficacy of Capricor’s twice-rejected Duchenne drug
Contrary to Capricor Therapeutics’ 2025 claims, the FDA said the company’s stem cell treatment for Duchenne muscular dystrophy did not meet Phase 3 trial objectives. Advisers approved it anyway based on a signal of efficacy and unmet patient need; full approval hinges on an ongoing Phase 3 readout expected 2027.
FDA approves Moderna’s mFlusiva — first mRNA flu shot ever
The FDA approved Moderna’s mFlusiva, the first flu shot built on mRNA technology — the same platform as COVID-19 vaccines. Moderna’s fourth U.S. vaccine. Some doses expected to be available this flu season. The approval caps a remarkable turn of fortune for a technology long targeted by vaccine skeptics.
A month in, CMS won’t tell patients which digital providers offer Medicare ACCESS
One month after the Medicare ACCESS chronic-disease model launched, CMS won’t publish a list of participating digital providers — leaving patients unable to find out which telehealth companies they can use under the new benefit. Transparency gap undercuts one of CMMI’s flagship chronic-care innovations.
AI scribes in medical school: useful tool or learning crutch?
As hospitals race to adopt AI scribes to ease clinician burden, medical schools are restricting access for trainees. Educators are concerned that offloading clinical note-writing to AI could impair learning — even as they want future physicians well-versed in the technology.
Q2 health tech earnings: agilon swings to $14M profit; Health Catalyst falls 25%
Key Q2 prints: agilon swung to $14M net income (vs. $104M loss a year ago) on moderating cost trend; Health Catalyst fell 25% after cutting guidance following the VitalWare sale; Omada beat and raised; Privia dropped ~20% on CMS shared-savings timing; Oscar raised outlook; CVS beat but guided cautiously on 2027.
HCMC took $705M state emergency bailout after burning cash reserves
Hennepin County Medical Center burned through cash reserves amid a board-vs-elected-officials clash over budget cuts and a layoff ban. Minnesota dissolved the HCMC Board in 2025 and issued a $705M state emergency bailout. The AdventHealth / Intermountain Colorado JV is under AG review as a parallel safety-net stress test.
White House Budget Buries Threat to Health Disparity Research
White House budget proposal contains provisions that would strip federal funding for health disparity and equity research — buried in grantmaking language, researchers warn of unprecedented scrutiny.
FDA Launches Pilot to Speed Early-Stage Clinical Trials
FDA announcing a pilot program to accelerate early-stage clinical trial approvals — framed as a U.S. competitiveness move vs. China on drug development velocity.
Exclusive: The 79-Year-Old Who Got Lilly's Unapproved Obesity Drug
STAT reveals that a 79-year-old received Eli Lilly's experimental retatrutide via FDA "compassionate use" — and the WH won't say if the patient is Trump. Democrats press WH for answers.
OpenEvidence Adds FDA-Cleared AI to Detect Heart Disease
OpenEvidence, the AI clinical-decision tool for physicians, will add an FDA-cleared AI model for cardiac disease detection — expanding its diagnostic intelligence layer.
U.S. Health Spending Hits $5.7 Trillion
U.S. health spending jumped to $5.7 trillion — GLP-1 drugs are a major factor, but not the only one. Sets the macro context for every payor and provider conversation FHG has.
Can AI Crack the Sudden Cardiac Death Mystery?
AI is being applied to one of medicine's oldest mysteries — why fundamentally healthy people drop dead. New models spotting highest-risk patients before the event.
FDA's Breakthrough Pipeline Fills With Generative AI Devices
FDA's breakthrough-device pipeline is now dominated by generative AI applications — a structural shift in the regulatory posture toward AI in clinical settings.
Proposed CDC Office Could Tighten Political Control at Agency
A proposed new CDC science office would centralize control over the agency's public communications — the office is hunting for funding and remains in limbo, but alarming to researchers.
White House Interest in GLP-1s Extends to a Lung Disease
GLP-1 drugs are attracting attention for a lung disease connection — White House interest broadening beyond obesity. Another signal of GLP-1 policy momentum.
Jails Are Fielding a Dangerous New Type of Drug Withdrawal
Medetomidine — a veterinary sedative entering the illicit drug supply — causes rapid, dangerous withdrawal. Jails are not equipped for the complex treatment protocols required.
Democrats Press White House: Who Got Extraordinary Access to Lilly's Obesity Drug?
Democrats formally ask the White House to disclose who received special access to Lilly's experimental retatrutide — STAT's Jun 23 exclusive escalates into a congressional inquiry.
Lifers hits 1M views; Midjourney enters medical
Consumer health media milestone: Lifers crosses 1M views, validating peer-to-peer health storytelling as a distribution model. Midjourney pivots into radiology, pathology, and medical education via synthetic imaging — reimbursement is the defining wall; new AI modalities face the same payor barrier that has stalled liquid biopsy for 15+ years. *GOLD: AI-in-health reimbursement-barrier thesis; Forwarded candidate — AI Measured or What I’m Watching column.*
The Midjourney takes the internet will hate
Midjourney opens a full-body ultrasound spa in SF — physicians pile on about incidentaloma risk. Farr’s counterargument: the system billing $27K/family/year has weak standing to call prevention dangerous. The real killer is reimbursement: liquid biopsy is 15+ years in and still fighting for payor coverage — no clinical promise survives the payor wall. *GOLD: Core FHG Pillar 4 — sick-care vs. prevention, reimbursement barrier as the structural chokepoint; Reimbursement-opoly Community Chest candidate.*
Lilly’s latest 340B salvo; Connie Health rolls up its 10th MA brokerage
Eli Lilly escalates contract pharmacy restrictions under 340B — directly hitting FQHCs and safety-net hospitals. Connie Health acquires its 10th Medicare Advantage brokerage, continuing rapid consolidation of the MA distribution channel. Plus: positive data and coverage signals in the GLP-1/peptide space.
Federal grant delays could jeopardize essential disability services, research
Hundreds of disability researchers across the U.S. are worried about their jobs and the future of their institutions as federal grant delays bite into essential services and research programs — a direct consequence of the funding freeze across HHS agencies. Extends the NIH-grants arc and the federal workforce disruption thread.
The ‘never event’ that’s been happening more frequently
STAT’s full investigative narrative: amid confusion over Pfizer’s emergency penicillin program, a newborn is diagnosed with preventable congenital syphilis. The concrete case study from STAT’s reporting on how an 800% increase is happening in hospitals that should know better — public health infrastructure gaps, drug shortages, and procedural failures stacking up at the bedside. Extends the Jun 15 congenital syphilis investigation series.
How AI Could Turn Primary Care Into a Referral Machine
A structural provocation for FHG’s primary care orbit — if AI-assisted triage flags more conditions than a clinician would under time pressure, the net effect may be more specialist referrals, not fewer. The technology is advancing quickly; the bigger question is whether the health care system’s financial incentives are ready for it. Direct signal for the Clinical Network lens on AI’s role in the referral chain.
OhioHealth Settles; CMS Recalculates Stars
OhioHealth reaches a settlement; CMS recalculates Medicare Advantage Star ratings — a recalculation that reshuffles quality-bonus payments and plan positioning for 2027. Payor intelligence: Star-rating moves are among the highest-leverage signals in the MA plan market.
LucyRx and Abarca Health pair off to challenge the Big 3 PBMs
LucyRx (prescription pricing transparency) and Abarca Health (claims processing + PBM tech) mount a combined challenge to Express Scripts, CVS Caremark, and OptumRx. A structural signal for FHG’s reimbursement thesis: if the Big 3 PBM model faces a credible challenger pair, the downstream reimbursement rules are live.
West Health–Gallup: health care affordability stress is deepening
A new West Health–Gallup survey finds health care affordability stress deepening across the American population — a macro signal for FHG’s payor and health system client conversations. When affordability is the defining patient experience, value-based care and network performance are not abstract; they are the answer the market is asking for.
Senate Democrats demand federal vaccine policy records
Senate Democrats have launched a formal demand for federal vaccine policy records — a congressional oversight move targeting Kennedy-era HHS vaccine policy shifts. A signal for FHG’s federal engagement orbit: active oversight of HHS vaccine decisions shapes the public health and population health context our payor clients navigate.
How a biotech turned a trial failure into an AI model
A biotech company converted data from a failed clinical trial into a predictive AI model — identifying which patient phenotypes respond best to a given treatment. The pivot reframes trial failure as a training asset. Relevant for FHG’s AI-in-health-care narrative and payor clients evaluating AI-assisted clinical trial enrollment and specialty benefit design.
FDA refreshes AI-enabled medical devices inventory — a regulatory snapshot of the field
The FDA has updated its official list of AI-enabled medical devices authorized for U.S. market use — a running inventory of the regulatory surface area of AI-assisted clinical tools. The list grows with every news cycle, and with it the reimbursement, liability, and oversight questions that follow each new clearance. A Pillar-4 signal for the FHG ecosystem map.
Do wearables actually help people with cardiovascular disease?
New evidence scrutinizes whether consumer-facing cardiac wearables deliver measurable health outcomes for people living with cardiovascular disease. A Morning Rounds lead examining the clinical evidence gap between wearable adoption and demonstrated benefit — directly relevant to remote-monitoring reimbursement and payor coverage policy.
FDA issues warnings on telehealth prescribing practices
The FDA has issued warnings targeting telehealth prescribing practices — a directional signal of federal regulatory attention on virtual-care prescription channels as telehealth policy flexibilities approach their next legislative junction. Pairs with the steady state-level PA and coverage rulemaking wave.
FDA reverses course on a rare disease gene therapy
The FDA has reversed its prior opposition to a rare disease gene therapy, reopening a U.S. approval pathway. Specialty benefit-design signal for health plans evaluating coverage of emerging therapies in rare-disease categories — where one FDA decision can immediately trigger plan coverage-decision timelines.
UniQure’s Huntington’s gene therapy cleared for formal FDA review
The FDA reversed its prior opposition to UniQure’s Huntington’s disease gene therapy, creating a path for formal U.S. approval filing. High-profile rare disease category with strong patient advocacy; reimbursement and coverage decisions follow swiftly when the FDA grants a formal review pathway — a specialty coverage watch item.
Is Abridge ‘patient‑centered’? Scrutinizing the rebranding amid Nvidia deal and nurse expansion
Patients don’t have direct access to Abridge — they see notes through EHR summaries. Abridge is training on de-identified patient data with Nvidia open-weight models, expanding into nursing documentation, and bidding to be the “everything-app for health care” including clinical trial enrollment.
Health care AI is inflating costs — David Brailer’s warning, PwC 9%, Indiana’s coding law
David Brailer (America’s first health tech czar) argues in Health Affairs that AI will accelerate health care inflation. 70% of health plans cite AI tools as a top-3 cost driver (PwC). Indiana law effective July 1 bars AI downcoding AND requires human review on AI-generated claims.
Nature paper: commercial chatbots outperform OpenEvidence and UpToDate’s AI on clinical benchmarks
General-purpose LLMs beat specialized clinical decision-support tools on a Nature benchmark. OpenEvidence posted a closed-comments LinkedIn response, signaling a methodology dispute.
Cheap GLP-1s might be hard to take from seniors
The generic GLP-1 pipeline is arriving, but Medicare seniors face structural barriers: Part D formulary restrictions, cost-sharing structures, and CMS coverage policy gaps may make lower-cost versions hard to access even when available. Directly relevant to MA plan formulary design and the weight-loss drug coverage debate.
The OIG bombshell, and a Medicare chart
OIG reviewed a single month of MA claims data and the picture is damning — the industry’s financials do not square with public claims about MA efficiency. Key chart: Medicare spending breakdown by plan type. Archelle Georgiou (former UHC executive) reinforces prior WSJ reporting. *GOLD: extends the MA denial arc with financial-analysis framing; pairs with the Jun 11 federal-investigation exclusives already on the board.*
What’s behind the 800% increase in congenital syphilis?
Major STAT investigation into the dramatic rise in congenital syphilis rates. Systemic failures driving an 800% increase: public health infrastructure gaps, drug shortages, and access to penicillin. A national-scope examination of preventable harm at the intersection of public health funding and provider access.
States follow Trump’s Medicaid fraud playbook — people with disabilities pay the price
States are applying federal anti-fraud language to deny care to Medicaid enrollees with disabilities. Advocates say “fraud” is being used as pretext to restrict access. Downstream consequences of Medicaid enrollment scrutiny on vulnerable populations — directly tied to the OBBB Medicaid-cut dynamic.
Post-acute care denials: same stark patterns, three years on
More than three years after Mike Reddy and Casey Ross began documenting post-acute care denial patterns, the picture remains unchanged — insurers continue to deny skilled nursing, rehab, and home health at scale. *GOLD: durable-pattern anchor for the MA denial arc; extends the Jun 11 federal-investigation exclusive and OIG appeal-reversal data; Pillar 4 + Reimbursement-opoly Community Chest candidate.*
HFMA 2026: hospital billing executives feel the whiplash
Hospital billing leaders at HFMA 2026 describe a year of “whiplash” — constant policy reversals, reimbursement volatility, and the administrative toll of keeping pace with an unstable regulatory environment. A Workforce signal on the finance side of health system operations.
Outpatient care is Medicare’s real fiscal drain — Georgetown and Trustees data reframe the Part A narrative
Georgetown researchers and the Medicare Trustees report point to outpatient care — not inpatient — as the dominant driver of Medicare expenditure growth, reframing the Part A insolvency debate. A Pillar 4 signal on where the reimbursement pressure is actually building.
Bridge program: $4.4B in the CMS data, and no cost estimate from the agency
A specific line in Medicare data shows $4.4 billion attributed to the Bridge GLP-1 coverage program, yet CMS has declined to release its internal cost estimates — a transparency gap at the center of the weight-loss drug coverage debate. Extends the Jun 1 Bridge program coverage arc.
Alcohol study suppressed by Trump officials is published in scientific journal
The alcohol-risk study that HHS officials discarded and then responded to coolly is now formally published — scientists pushing back against government suppression of findings. *GOLD: Deadliest Drug arc piece 8 — suppressed May 13 → published Jun 9 → HHS cool response Jun 11 → journal publication confirmed Jun 13.*
The biggest environmental factor impacting children’s brain health
A Morning Rounds lead on the environmental exposures most responsible for children’s neurological development — likely lead and other toxics — with policy implications for CMS and state public-health programs.
Exclusive: WHO chief profoundly concerned after DRC visit — war a greater threat than Ebola
In a rare one-on-one interview, Director-General Tedros Adhanom Ghebreyesus speaks on the Ebola outbreak and other health crises in DRC, where armed conflict may pose a greater threat than disease itself.
“I’ve spent 40 years in research. I have never seen a threat to science like the new grantmaking rule”
Former Smithsonian Secretary and Cornell president Skorton argues the OMB’s proposed overhaul of uniform guidance would hand political appointees content-based control over NIH grant awards — turning federal research funding into a patronage lever. *GOLD: extends the Schedule F / NIH-grants arc (Jun 4–5 civil-service + grants EO GOLD cards); OMB uniform-guidance overhaul is the financial chokepoint the reclassification order enables.*
HHS responds coolly to paper on alcohol risk
HHS pushes back — guardedly — on published findings from the formerly suppressed alcohol-risk study, saying the science has limitations. *GOLD: Deadliest Drug arc piece 7 — suppressed May 13 → published Jun 9 → federal government response in four days; the political-science-resistance arc runs from MetALD through federal pushback.*
A suspicious denial pattern in Medicare Advantage
Wilkerson’s D.C. Diagnosis column maps MA prior-authorization denial patterns against the trustees report and rising prescription drug costs — policy context flanking the day’s two MA federal-investigation exclusives. Also covers Medicare Advantage barriers to rehab care for seniors.
Diabetes association leader apologizes for expulsion of members, pledges to rebuild trust
ADA CEO issues a public apology for removing members who protested NIH funding cuts at the annual convention, pledging to rebuild trust. *Companion to Jun 9 ADA uproar card — clinical-society reckoning as federal research-funding collapse hits organized medicine’s own annual events.*
Exclusive: Federal investigation finds Medicare Advantage barriers to doctor-recommended care
A federal investigation finds MA plans are systematically blocking care that physicians recommend — the strongest federal probe of MA prior-auth denial behavior to date. Companion to the same-day MA denials-reversed-on-appeal exclusive. *GOLD: exclusive federal probe + Pillar 4 anchor — MA structural denial as a reimbursement-integrity failure; Reimbursement-opoly Community Chest candidate.*
Exclusive: Medicare Advantage insurers block care for seniors only to reverse denials on appeal
MA insurers systematically deny care then reverse course when seniors appeal — exposing the denial pattern as strategically motivated, not clinically justified. Also: a nonprofit acquires an experimental cancer drug to preserve patient access. *Companion to same-day federal-investigation exclusive; appeal-reversal data is structural proof that denials are administrative, not medical — direct MA care-burden anchor.*
AMA and lawmakers push back on AI care denials — plus Noom RCT validates digital weight-loss app
The AMA and congressional allies press for guardrails on AI-driven prior-authorization denials — the legislative complement to the day’s two MA denial exclusives. Also: an RCT shows Noom’s digital weight-loss program works in a controlled study. *Cross-flash with Third Horizon Tea Leaves Jun 11 (AMA AI story in Access & Coverage lane) — 2 curators.*
Your sepsis algorithm shouldn’t require a time machine
Clinical AI trained on past data fails when patient populations shift — sepsis algorithms are especially vulnerable to temporal drift. Also: Anthropic’s fix for science agents and AI patient scribes. *GOLD: ClinicianPulse-adjacent — extends the May 15 Katie Palmer GOLD card on sepsis-algorithm reimbursement mechanics; two STAT treatments of sepsis AI inside the 60-day window.*
Physician burnout at 46%, depression at 20% across 5,159 physicians — 29 specialties
A survey of 5,159 physicians across 29 specialties found burnout remains widespread: 46% reporting burnout, 20% experiencing depression. The numbers are clinician-workforce anchors for FHG’s ClinicianPulse and IPW positioning — the lived reality behind every burden-reduction narrative.
Meta ordered to pay $900M+ in landmark New Mexico child-safety case
A New Mexico judge ordered Meta to pay more than $900 million: a $567M fund to address harms linked to Facebook and Instagram, plus $375M in previously imposed civil penalties. One of the largest youth mental-health liability verdicts against a platform company.
D.C. uses opioid settlement funds to cover Medicaid costs — critics warn of diversion
Washington D.C. plans to use millions from opioid lawsuit settlements to backfill Medicaid costs and addiction-treatment programs previously funded from its general budget. The D.C. Opioid Abatement Advisory Commission and advocates criticized the move as diverting funds from their intended addiction-treatment purpose.
Medicaid/ACA enrollment declines hit insurers and hospitals — uncompensated-care wave coming
Early earnings reports show declining Medicaid and ACA marketplace enrollment, higher medical costs, and increased pressure on providers as more patients lose or change coverage. Industry leaders warn hospitals could see more uncompensated care and may shift costs to commercially insured patients. The full financial impact will unfold over coming quarters.
Trump revives “public charge” rule — Medicaid use could deny green cards in September
The Trump administration revived stricter public charge standards that allow immigration officials to deny green cards to applicants deemed likely to rely on Medicaid, food assistance, or housing support. Critics say it will discourage eligible immigrant families from seeking essential health care. Effective September after Federal Register publication.
GE HealthCare & Catholic Health sign $500M, 10-year imaging and AI technology partnership
1,300+ new imaging, diagnostic, and AI-enabled technologies across Catholic Health’s hospitals and outpatient sites — radiology, cardiology, oncology, neurology, women’s health. Includes cloud-based digital solutions, predictive maintenance, and workflow optimization. One of the larger health-system IT partnerships of 2026.
CMS tightens RPM/RTM billing — third-party vendors lose reimbursement access in 2027
CMS proposed limiting remote patient monitoring and remote therapeutic monitoring payments to services delivered by clinical staff employed by the billing practice — not third-party vendors. If finalized (2027 Medicare Physician Fee Schedule), many practices would need to bring remote monitoring in-house. Fraud-prevention framing.
CDC gets first full-time director in nearly a year: Dr. Erica Schwartz, 51–44
The Senate confirmed Dr. Erica Schwartz as CDC director. A former deputy surgeon general, Schwartz supports childhood vaccine safety and effectiveness while also endorsing elements of the “Make America Healthy Again” agenda. She takes over an agency reduced by RFK Jr. workforce cuts, ongoing disease outbreaks, and vaccine-policy scrutiny.
More than 1-in-3 patients abandoned their first buprenorphine prescription in 2024
JAMA Network Open: 25.8% of patients failed to fill their first buprenorphine OUD prescription within 30 days; overall abandonment was 35%+, up from 19% in 2020. Higher rates among commercially insured patients and those with larger pharmacy deductibles. Financial barriers and access disparities are worsening, not improving.
Tea Leaves: June 22, 2026
Walmart and Sam's Club are launching health care service initiatives — a signal of continued retail health sector investment. Tea Leaves covers access, coverage, and market fronts.
Tea Leaves: June 24 — Bipartisan Senate Drug Cap Proposal
Bipartisan Senate proposal to cap drug costs surfaces in this morning's policy brief — a rare cross-aisle move on pharmaceutical pricing that could reshape payor negotiations.
Tea Leaves: June 25 — CareQuest Institute Report
CareQuest Institute publishes a new report — oral health access and coverage equity in focus. Tea Leaves surfaces data and access trends across the health care landscape.
Tea Leaves: June 26 — Summer Break Ahead
Tea Leaves announces a short summer break — returning after the holiday. Final morning dispatch before the pause covers health industry activity for the week.
Tea Leaves, June 17 — Life Sciences: new JAMA Internal Medicine viewpoint
The June 17 Tea Leaves led with a Life Sciences section flagging a new JAMA Internal Medicine viewpoint. Full body unavailable in this bake cycle (thread body exceeded sandbox cap); surface note only. Full triage available via Sift the Bothans. Third Horizon’s Life Sciences lane typically covers clinical evidence, specialty practice patterns, and coverage-relevant research.
Maine and other states ordered to revise payor coverage and prior authorization rules
State-level payor regulation is tightening: Maine and peer states are being required to revise prior authorization or coverage requirements — accelerating wave of state-driven MA and commercial plan oversight.
Federal judge strikes down CMS 2025 ACA marketplace rule provisions
A federal court struck down several CMS 2025 rule provisions, finding they exceeded agency authority. Blocked: the $5 auto-re-enrollment penalty, a shortened open-enrollment period, and stricter eligibility checks. Regulatory tailwind for marketplace coverage stability.
Commercial health care costs rising 9% in 2027 — PwC “Behind the Numbers”
PwC projects commercial group medical cost trend of 9% for 2027, the highest in nearly two decades. Drivers: AI-enabled revenue-optimization tools (the irony — AI sold as a cost-cutter is among the first inflators), pharmacy spend, behavioral-health utilization, No Surprises Act disputes, and labor costs. *GOLD: ⇆ 2 curators (TH + HTN Jun 12 already on the board); Reimbursement-opoly candidate.*
48% of large employers plan to shift health benefit costs to workers in 2027 — Mercer
Mercer survey: 48% of large U.S. employers plan benefit changes that increase worker costs in 2027. Projected 6.7% increase in employer health benefit costs overall. Pairs with the PwC 9% trend card — the cost-escalation signal is now coming from both the supply (provider) and demand (employer) sides.
OIG: MA insurers frequently deny post-acute care — UHC, Humana, CVS lead in denials
OIG report documents MA insurers denying post-acute care at high rates, with UnitedHealth, Humana, and CVS rejecting care at significantly higher rates than peers. Many denials overturned on appeal. Third Horizon surfaces the same OIG finding that STAT (Jun 11) and Rock Health (Jun 15) covered independently. ⇆ 3 curators on the MA denial arc.
Behavioral health integration gains traction in five major health systems
UCHealth, Mass General Brigham, Providence, and peers are integrating behavioral health into routine primary care. Early data shows improved outcomes and reduced overall utilization — a structural argument for the integrated-care model that FHG’s clinical-network lens applies directly.
CMS tightens oversight of Medicaid demonstration waivers starting 2027
Starting 2027, all new Medicaid waivers and renewals must be certified budget-neutral by the CMS chief actuary, with more detailed financial projections required. Signals tighter federal scrutiny of state Medicaid flexibility — directly shapes the value-based care waiver landscape.
Tea Leaves: AI adoption in Health IT is accelerating
Third Horizon’s Tea Leaves leads on AI adoption velocity in Health IT: clinical-AI deployment is accelerating faster than readiness frameworks anticipate. *Cross-source with HTN Jun 12 (Abridge’s ambition) — 2 curators on AI deployment velocity in the same news cycle.*
Tea Leaves: AMA pushes back on AI-driven care denials; access & coverage roundup
Third Horizon’s Tea Leaves leads with Access & Coverage: the American Medical Association pressing for guardrails on AI-generated prior-auth denials. *Cross-source with STAT Morning Rounds Jun 11 (same AMA AI-denial story) — two curators on AI-driven denial pushback in the same news cycle as the two STAT MA federal-investigation exclusives.*
Tea Leaves: Efforts to make medical records easier to share
Third Horizon’s Tea Leaves leads on Health IT: initiatives making medical records more portable and accessible to patients and providers — the ongoing interoperability push in the context of the 21st Century Cures Act’s data-access mandate.
Employer health market white hot; ACCESS model math doesn’t pencil for digital leaders
Omada and Hinge Health publicly said they couldn’t make ACCESS rates work. HTN reads this differently: the employer market they sell into is white hot. Omada +43% rev / +45% members YoY; Hinge +53% rev / +24% clients YoY. HTN predicts ACCESS becomes attractive only when the employer market cools.
Vytalize Health on track for $70M+ adj. EBITDA in 2026 — a VBC bright spot
Co-founders Faris Ghawi and Dr. Amer Alnajar presented at HTN: $50M adj. EBITDA in 2025, growing to $70M+ in 2026 (+40% YoY), across 400,000+ patients in 30 states spanning Medicare, Commercial, Medicaid, and MA. After a challenging PY2024 ACO REACH run, Vytalize has righted the ship.
ACO REACH PY2024: $2.5B gross savings — 2021-vintage ACOs carry the result
CMS REACH PY2024: $88.04 PBPM gross savings, 24% YoY. 2021 cohort drove it: 6.5% net savings rate vs 2.8% for 2022, 2.4% for 2023. Leaders with >10% net savings include Oak Street, agilon, CenterWell, VillageMD. Heavy losses concentrated at CVS and Vytalize (~$170M combined). The model sunsets end-of-2026.
SCAN sues CMS over Stars rating recalculation — $125M at stake
SCAN filed in DC District Court, arguing CMS’s partial implementation of the Clover ruling cost SCAN $125M in bonus payments (should have been 4.5 Stars, not 4.0). SCAN: “the Star Ratings program went off the rails years ago.” Elevance, SCAN, and others are now actively litigating the same CMS methodology.
Kaiser nurses raise patient safety concerns over AI call center monitoring
California nurses flagged concerns over Kaiser Permanente’s AI tools tracking call length and time-to-answer. KP denied using Average Handle Time for performance assessment. HTN frames it as a Goodhart’s Law case study: AI productivity tools will paradoxically increase middle management headcount as gaming multiplies.
OpenEvidence expands to NYP, Columbia, Weill Cornell — health system shift
OpenEvidence announced partnerships with New York-Presbyterian, Columbia University, and Weill Cornell Medicine. HTN reads this as OpenEvidence confirming its pivot from individual physicians to health systems as the primary distribution model for clinical AI.
Employer health market white hot — ACCESS model waits for the cycle to turn
Bank of America spends ~$250M/year on GLP-1s — ~13% of its $2B total health care spend for 200,000+ employees. CEO Brian Moynihan: “The long-term health benefits make it a good investment.” HTN flags models like Ilant Health managing GLP-1 appropriateness programs as direct beneficiaries.
CMMI eyeing MA demonstrations for Stars, Risk Adjustment, and Value-Based Care
Per InsideHealthPolicy: CMMI is considering Medicare Advantage demonstrations for Stars, Risk Adjustment, and VBC — perhaps the administration’s only move for meaningful short-run change amid ongoing litigation and a Congress focused on appropriations. Small-group ACA premiums up 14% median (from 11% a year ago).
Datavant $2.5B recap to fold in SmarterDx — New Mountain reshapes its health IT stack
Datavant’s strategic review with JPM became a $2.5B recapitalization. Once complete, Datavant folds in SmarterDx (a New Mountain Capital portco also bundled with Thoughtful.ai, Access Healthcare, and Machinify in the failed Thoreau transaction). New Mountain is also marketing Machinify separately.
Hinge Health acquires Cylinder Health for $105M — GI market push raises platform questions
Hinge acquired virtual wraparound GI-care startup Cylinder (formerly Vivante Health) for $105M cash — ~4.7x revenue on expected $20-25M 2026 revenue. PHTI’s GI report flags thin clinical evidence. HTN: the move echoes the Livongo risk — winning on go-to-market until you don’t. ¶ Cross-source: MTS, Aug 7.
Elevance high-cost claims: 0.78% of members drive 34% of spending
Elevance’s high-cost-claims report shows a $15.4M single claimant in 2025 (large-group/commercial book). High-cost claimants (>$100k) are only 0.78% of members but account for 34% of total spending. A stark concentration-of-spend data point directly relevant to FHG’s population stratification and risk-adjustment work.
Cadence $100m · a16z Backs Prosper · KaufmannHall Bad Debt Up
Cadence (chronic-condition digital health) closes $100m Series C led by Spark Capital at $1.2bn. a16z backs Prosper for back-office voice AI. KaufmannHall Flash Report: bad debt and charity care rising.
Assort Health $120m · Double-Digit ACA Premiums · Stop-Loss Lasering
Assort Health raises $120m Series C at $1.2bn for AI patient-journey agents. Double-digit ACA premium increases signaled ahead. Stop-loss lasering trend accelerating.
Cityblock + Homeward · Superpower Growth · $9T Health Spend by 2034
Cityblock and Homeward announce a deal — two value-based care platforms consolidating. Superpower (proactive health concierge) reporting strong growth. CMS projects national health expenditures hit ~$9T by 2034.
Klomp Nominated HHS Dep Sec · Updoc FDA Win · Hera $27m
Chris Klomp nominated as HHS Deputy Secretary. Updoc wins FDA clearance for AI clinical documentation. Hera raises $27m.
“We’re going to end up with a two-tier system” — MultiCare CFO at HFMA
Decades of CMS underpayment is structurally bifurcating health care: one system for commercial + out-of-pocket, another for Medicare + Medicaid. MultiCare CFO James Lee’s HFMA warning is the FHG “broken machine” thesis in a CFO’s own words. *GOLD: Forwarded cold-open candidate; The Number That Matters.*
Key blow to anti-tiering and steering clauses — 18% hospital price reduction potential
A ruling deals a significant blow to anti-tiering/steering and all-or-nothing contracting clauses. Research projects 18% hospital price reduction and 6.5% premium drop if clauses go. HTN calls it a “massive tailwind for alternative plan design” — and for directing members to high-performance Clinical Network entities. *GOLD: directly strengthens the FHG Clinical Network value prop.*
Thoreau acquires Ensemble Health Partners for ~$12B — AI-enabled RCM consolidation
Matt Holt’s Thoreau (PE investment platform) acquires AI-enabled RCM leader Ensemble for ~$12B — Ensemble had been on a dual-track IPO/M&A process. Thoreau positioned for AI-centric health admin bolt-on acquisitions. *GOLD: largest PE health-tech RCM deal of 2026; CRG/reimbursement-intelligence thesis context; Joe Mozden orbit adjacent.*
AI scribe in the wild — “if I hadn’t been paying attention, I probably wouldn’t have noticed”
First-person account of encountering an AI scribe during a clinical visit. The tool faded into the background — HTN frames that as the right signal for ambient infrastructure. Expansion beyond early-adopter physicians is the next adoption test for the Clinical Network.
eviCore’s exit from prior authorization leaves a structural market gap
The exit and consolidation of eviCore — one of the dominant independent prior-authorization management vendors — is fragmenting a market that payors increasingly want to own in-house. Structural signal for FHG’s Clinical Network analytics: who controls prior authorization controls the data that defines network performance and the leverage that shapes coding and claims outcomes.
Copay-only plan designs emerge as a benefit-innovation signal
Health plans are testing copay-only structures — no deductible, flat copay at point of care — as a consumer-facing simplification play and as a competitive differentiator in employer markets. A direct FHG reimbursement-modeling signal: plans moving to copay-only designs reshape provider incentives, utilization patterns, and the coding and billing environment FHG’s analytics products serve.
OpenLoop builds “Shopify for telehealth” — modular infrastructure for virtual care
OpenLoop is positioning its platform as the infrastructure layer for telehealth providers — a modular “Shopify for telehealth” model enabling virtual care operators to build on a standardized stack. Structural lens for the telehealth-enablement market and a network-design implication for plans evaluating virtual-first care delivery.
Thoreau to acquire Ensemble Health Partners for $12B
A $12 billion acquisition of Ensemble Health Partners (RCM) by Thoreau signals continued consolidation in health IT. One of the larger health tech M&A transactions of 2026.
GLP-1 utilization management as a service: emerging payor-facing business model
GLP-1 prior authorization, step therapy, and adherence management packaged as a managed service for health plans. Directly relevant to MA and commercial plans managing GLP-1 cost and utilization pressure.
BCBS plans face operating margin pressure
Blue Cross Blue Shield plans reporting operating margin headwinds. Background context for the broader payor-market environment as MA pullbacks and commercial cost pressure compound.
Is 2032 setting up as a health care election?
Thesis: health care will be a central issue of the 2032 presidential election — specifically the downstream consequences of OBBB Medicaid cuts, MA denial patterns, and cost-shifting to workers crystallizing into a political inflection. The author encourages thinking now about how that dynamic shifts opportunities in the sector.
Abridge bids to be health care’s “clinical intelligence layer” — Lilly invests, Nvidia foundation model
Abridge positions itself as the ambient AI layer beneath all of clinical medicine — not just documentation. Eli Lilly invests for clinical trial navigation; Nvidia’s foundation model outperforms general AI on clinical tasks. *GOLD: ClinicianPulse-adjacent; “clinical intelligence layer” framing is the strategic claim; cross-source with Second Opinion Abridge–Epic landmark Jun 13.*
Hinge Health investor day: HingeSelect, Rule of ~60, stock up 62% since IPO
Hinge Health’s investor day featured HingeSelect (a self-pay offering), the “Rule of ~60” commercial model framework, and a 62% stock gain since IPO — a bullish signal for virtual MSK care and the employer benefits market.
Hawai‘i’s payvidor crossroads: HMSA and HPH eye “One Health Hawai‘i”
Hawai‘i’s two dominant health entities — HMSA (insurer) and HPH (health system) — are exploring a merger the governor is backing under the banner “One Health Hawai‘i.” VBC advocates and 3PC proponents are already in tension over what it means. A payvidor formation signal in a uniquely captive state market.
Abridge’s ambition; PwC predicts 9% medical trend growth in ‘27
Two signals: Abridge signals expansion beyond ambient documentation into a broader clinical AI platform — ClinicianPulse-adjacent. PwC predicts 9% medical trend growth in 2027 — a Pillar 4 signal on rising health care costs. *Cross-source with Third Horizon Jun 12 (AI adoption accelerating) — 2 curators on AI deployment velocity.*
Clover up ~14% with new 4.5-star rating; Hinge is a “rule of 60” company; Abridge × Nvidia foundation model
Three signals: Clover Health’s MA star-rating pop to 4.5 stars (+14% stock); Hinge Health is a “rule of 60” company (60-day contract, 60-day ramp, 60-day revenue); and Abridge announces a foundation model co-developed with Nvidia. *GOLD: Abridge–Nvidia is clinically significant — ambient clinical-AI foundational infrastructure, ClinicianPulse-adjacent.*
WISeR rebuked, Alignment’s stock pops 25%, and payer problems in Hawai‘i
Three signals: WISeR (workforce intelligence platform) draws regulatory rebuke; Alignment Health’s stock surges 25% on earnings; and payer-network access problems surface in Hawai‘i. MA-market operational-health watch.
Hinge Health acquires Cylinder Health for $105M — entry into GI market
Hinge Health agreed to acquire Cylinder Health, a virtual-first digestive health care provider, for $105M in cash. Hinge has seen 53% revenue growth YoY in the employer market. HTN reads the GI acquisition skeptically: pushes Hinge toward a multi-condition platform, echoing the Livongo risk. ¶ Cross-source: HTN.
Carlyle / Acentra Health acquires FEI Systems — Medicaid and human-services tech
Carlyle-backed Acentra Health acquired FEI Systems, a provider of cloud-based Medicaid and human-services technology spanning LTSS, HCBS, and behavioral health. Acentra continues to build out its government-health-services platform through acquisition.
Function Health raises $450M from General Catalyst — 160+ biomarker + imaging platform
Function Health, a membership platform offering 160+ biomarker lab tests plus MRI and CT imaging across 200+ U.S. locations, raised $450M led by General Catalyst. One of the largest digital health rounds of 2026, signaling continued investor appetite for comprehensive personal health data.
Stone Point / The Difference Card acquires HealthCorum — payor analytics play
Stone Point Capital’s The Difference Card acquired HealthCorum, a health care data-analytics company providing provider quality scores and AI-powered care navigation for payors. Bailey & Company served as exclusive advisor. Payor analytics M&A remains active.
Eir Partners invests in ClaimsBridge and acquires DialysisPPO — self-funded plan stack
Eir Partners Capital made a strategic investment in ClaimsBridge (claim and network technology for TPAs) and acquired DialysisPPO (dialysis cost-containment for self-funded plans). Builds out a specialty cost-containment platform targeting self-insured employers.
Thoreau Group to Invest in Ensemble Health Partners (Revenue Cycle)
Thoreau Group making a strategic growth investment in Ensemble Health Partners — a revenue cycle management platform for health care organizations. RCM consolidation signal.
Abarca Health + LucyRx: Two Independent PBMs Merge
Abarca Health and LucyRx — two independent pharmacy benefit managers — announced a merger. Independent PBM consolidation in the post-FTC scrutiny environment.
Altaris to Acquire Simulations Plus for $375mm (AI Drug Dev)
Altaris agreed to acquire Simulations Plus — an AI-enabled modeling and simulation platform for drug development — for $375mm total consideration.
Assort Health Raises $120mm Series C at $1.2bn
Assort Health — AI agents platform for the patient journey — raised $120mm Series C led by Menlo Ventures at $1.2bn valuation.
Cadence Raises $100mm Series C at $1.2bn (Chronic Conditions)
Cadence — digital health for chronic conditions — raised $100mm Series C led by Spark Capital at $1.2bn.
Week in Review: June 12, 2026
MTS Week in Review coverage of health care deal flow, M&A activity, and financing rounds for the week ending June 12, 2026.
Researcher tricks Claude into providing medication tapering guidance
A researcher manipulated Claude into providing medication tapering advice — a category of clinical guidance the model is designed to avoid without clinician oversight. The documented jailbreak is a concrete demonstration that clinical AI guardrails can be bypassed. Directly relevant to any health system deploying AI in care workflows.
HHS Deputy Chief AI Officer Arman Sharma at Ai4: “defining technology of the 21st century”
Arman Sharma (HHS Deputy CAIO) framed AI as transformational for how health care operates at the Ai4 conference in Las Vegas. Also previewed: a conversation with Tony Ambrozie (SVP/Chief Digital Officer, CVS Health Pharmacy) on buy vs. build. The government’s AI posture under MAHA is shifting rapidly.
U.S. Health Spending Projected to Hit $9 Trillion by 2034
New CMS ahead-of-print projections: U.S. health spending will reach nearly $9 trillion — 20.6% of the entire economy — by 2034, up from today's $5.7 trillion baseline.
Buying Health AI? A Four-Part Framework
A field guide for health care organizations buying AI — and for the builders. Four-part framework for evaluating health AI vendors in an increasingly crowded market.
Updoc's FDA Win Raises the Stakes for Health AI Rivals
Updoc wins FDA clearance for AI clinical documentation — Second Opinion covers how this win reshapes the competitive landscape for health AI. Plus four questions with MIDI founder Joanna Strober.
Abridge announces Epic partnership — CEO Shiv Rao speaks
Abridge’s landmark Epic integration deal marks a watershed in AI clinical documentation — CEO Shiv Rao speaks on the company’s ambitions. *GOLD: ClinicianPulse-adjacent; Epic partnership reaches every Epic-using health system.*
Health care’s “sea of sameness” problem — a veteran comms pro sounds the alarm
Health care companies are drowning in a “sea of sameness” — generic brand language, identical positioning, and undifferentiated communications across the sector. A senior comms professional makes the case for why the industry’s messaging crisis is deeper than it appears. A Workforce signal on the organizational-identity side of the health tech stack.
If the ACCESS Model works, should it be expanded to Medicaid?
Experts inside and outside government weigh in on whether the ACCESS Model — a value-based primary care payment model — should be scaled to Medicaid. *GOLD: Pillar 4 anchor — the ACCESS Model is the federal payment-reform laboratory most directly aligned with FHG’s thesis on value-based care expansion; strong Reimbursement-opoly Community Chest candidate.*
Digital health raises $7.4B in H1 2026 — $1B ahead of H1 2025 pace
Rock Health’s H1 2026 tally: $7.4B VC invested in digital health, $1B ahead of the year-prior pace. Mega-deals (>$100M) remain the defining feature: 19 companies raised 45% of all capital. Signals continued investor conviction in large-platform plays despite broader market caution.
Counting Sheep: The Growing Business of Sleep Health Tech
Roughly 150 million Americans struggle to fall asleep — Rock Health's weekly covers the growing digital health sleep market, investor activity, and the startup landscape in sleep tech.
Denied by design — MA prior authorization under the microscope
Rock Health’s lead case: a stroke patient denied inpatient rehabilitation, reversed on appeal — the same pattern the OIG documented at scale. MA economics tightening as insurers pull back supplemental benefits. Identifies digital health opportunity in prior-auth workflow tools and appeals-support platforms. *GOLD: ⇆ 3 curators (Rock Health + STAT Jun 11 + Third Horizon Jun 15); Pillar 4 anchor; Reimbursement-opoly candidate.*